Alcon: completes acquisition of Aerie Pharmaceuticals
(CercleFinance.com) - On Tuesday Alcon announced that it had completed the acquisition of US-based Aerie Pharmaceuticals, in a deal that is designed to strengthen its position in ophthalmic pharmaceuticals.
Thanks to this transaction, the Swiss group will acquire the commercial rights to Rocklatan ophthalmic solution, as well as Rhopressa, an experimental Phase 3 treatment for dry eye.
In a statement, Alcon said that the acquisition will further strengthen its ophthalmic medicines business following the acquisition of Simbrinza from Novartis last year and Eysuvis and Inveltys from Kala this year.
Alcon intends to fully consolidate its new subsidiary.
As previously reported, the group used debt to finance the acquisition, which is estimated to be around 930 million dollars.
Copyright (c) 2022 CercleFinance.com. All rights reserved.